Chemed Corp stock hits 52-week low at $384.57

Chemed reported Q4 2025 EPS of $6.42 vs. $7.07 expected (≈9.2% miss) and revenue of $639.34M vs. $658.97M expected (≈3.0% miss). Shares are at a 52-week low (~$384.57), down ~34% over the past year; market cap is ~$5.3B and P/E is 21.17. RBC Capital downgraded CHE from Outperform to Sector Perform and cut its price target from $572 to $422, citing margin concerns in Roto-Rooter, though VITAS hospice shows positive momentum in Florida. Management's 17-year dividend growth is a positive signal, but near-term outlook appears pressured by operational/margin headwinds.

Analysis

Roto-Rooter’s margin sensitivity is the primary driver of downside optionality here: field-service businesses amplify small changes in labor, subcontractor availability, and parts inflation into outsized margin moves because pricing lags and fixed dispatch costs remain. That creates a bifurcated valuation between the stable hospice cash flows and the volatile plumbing business; in a stressed-rate or recessionary scenario the plumbing division will re-rate much faster than hospice, compressing consolidated multiples even if hospice fundamentals stay intact.

Second-order beneficiaries include private-equity acquirers and strategic buyers of stable hospice franchises — depressed parent multiples increase the chance of carve-outs or take-private activity on the hospice arm within 12–24 months, which would re-price the stock. Conversely, independent local plumbing contractors and franchisors could win share if national service brands retrench, tightening near-term pricing power and prolonging margin recovery for the corporate owner.

Key catalysts and risks: near-term directional moves will be driven by macro (Fed moves and recession signals) and quarterly operational updates on field margins and truck-roll productivity over the next 1–3 quarters. Structural reversals require either sustained margin improvement at the plumbing unit, a credible plan to separate assets, or lower market discount rates; downside tails include regulatory reimbursement shocks to hospice or a sustained labor-cost spike that proves persistent through two reporting cycles.

The consensus is pricing a multi-quarter operational slog into the equity, which makes outright equity short attractive but asymmetric option structures or relative-value pairs that isolate the plumbing risk preferable. Position sizing should assume higher-than-normal binary risk around quarterly prints and any formal strategic-review announcements.

Key Decisions for Investors

• Short CHE equity (3–9 month horizon): size small (1–2% long portfolio NAV exposure or 0.25–0.5% directional fund NAV), target 25–35% downside vs entry, stop at 10–12% adverse move. Rationale: capture continued margin compression and multiple contraction if field ops underperform; manage binary risk around strategic-review headlines.
• Pair trade — Short CHE / Long AMED or EHC (dollar-neutral, 3–9 month horizon): expected relative outperformance of 15–30% if hospice dynamics re-rate vs plumbing volatility. Size as market-neutral leg (e.g., $1 short CHE per $1 long AMED), stop pair if divergence narrows >10% intraday.
• Buy 6–9 month CHE put spread (debit-limited protection): use a moderate-width put spread to cap premium (risk = premium) and gain 3–5x payoff if operational slides persist. This limits carrying cost versus naked puts and hedges against quarterly downside surprises.
• Contrarian asymmetric long (12–18 month horizon): small position in long-dated CHE calls or call verticals (size 0.25–0.5% NAV) to capture upside from a potential hospice carve-out or rapid margin stabilization. Reward asymmetry justifies keeping premium exposure light; trim if share price recovers >30%.